AKDOĞAN, N. Et Al. 2024. Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis. EXPERT REVIEW OF CLINICAL PHARMACOLOGY , no.8 , 755-762.

AKDOĞAN, N., Balan, K., YALICI ARMAĞAN, B., GÜLSEREN, D., & DOĞAN GÜNAYDIN, S., (2024). Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis. EXPERT REVIEW OF CLINICAL PHARMACOLOGY , no.8, 755-762.

AKDOĞAN, NESLİHAN Et Al. "Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis," EXPERT REVIEW OF CLINICAL PHARMACOLOGY , no.8, 755-762, 2024

AKDOĞAN, NESLİHAN Et Al. "Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis." EXPERT REVIEW OF CLINICAL PHARMACOLOGY , no.8, pp.755-762, 2024

AKDOĞAN, N. Et Al. (2024) . "Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis." EXPERT REVIEW OF CLINICAL PHARMACOLOGY , no.8, pp.755-762.

@article{article, author={NESLİHAN AKDOĞAN Et Al. }, title={Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis}, journal={EXPERT REVIEW OF CLINICAL PHARMACOLOGY}, year=2024, pages={755-762} }